Aspira Women's Health Licenses Dana-Farber microRNA Signature; Firm Executes Reverse Stock Split
Aspira Women's Health has been evaluating Dana-Farber's microRNA technology for ovarian cancer detection since early 2021.
Gilead Sciences Acquires XinThera, Adds PARP1 Inhibitors to Oncology Pipeline
The acquisition will bring several oncology assets into Gilead's pipeline, including a PARP1 inhibitor that may enter clinical trials later this year.
ImmunoGen to Submit Phase III Trial Results of Elahere to Regulators in US, Europe
The positive results will be used to support a submission for initial approval in Europe and to convert to full approval in the US.
Relay Therapeutics' Early Data on Selective PIK3Cα Inhibitor Suggest Promising Tolerability
At AACR, researchers presented preliminary data from the Phase I ReDiscover trial, which suggested RLY-2608 could have a better safety profile than Novartis' Piqray.
Nuvectis Launches Phase Ib Study of HSF1 Inhibitor in ARID1a-Mutated Ovarian Cancer
The firm is evaluating NXP800 in roughly 50 patients with ARID1a-mutant ovarian cancers that are unresponsive to platinum-based chemotherapy.